File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy

TitleOfloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy
Authors
Issue Date1990
Citation
Antimicrobial Agents And Chemotherapy, 1990, v. 34 n. 2, p. 215-218 How to Cite?
AbstractThe efficacy of ofloxacin in preventing infection in neutropenic patients following cytotoxic chemotherapy was evaluated and was compared with that of co-trimoxazole. A total of 102 patients with hematological malignancies were randomly selected to receive either co-trimoxazole or ofloxacin. All patients were monitored for compliance, occurrence of infection, and drug-related side effects. A surveillance culture of a rectal swab was performed regularly. A total of 25 of the 52 patients (48%) who received co-trimoxazole and 11 of the 50 patients (22%) who received ofloxacin developed fever during the study period (P < 0.025). Gram-negative bacteremia occurred in nine patients in the co-trimoxazole group (17%) but in only one patient (2%) in the ofloxacin group (P < 0.05). No patient in either group had documented gram-positive bacterial or Pneumocystis carinii infection. Poor performance status was the only identifiable factor associated with an increased incidence of bacteremia. The surveillance study showed that significantly fewer bacterial strains were resistant to ofloxacin than to co-trimoxazole and that acquisition of resistance to co-trimoxazole was more commonly observed than was acquisition of resistance to ofloxacin. Significantly more patients had skin rashes following co-trimoxazole than ofloxacin treatment (P < 0.05). Ofloxacin was superior to co-trimoxazole in preventing infection in this population of neutropenic patients.
Persistent Identifierhttp://hdl.handle.net/10722/161826
ISSN
2015 Impact Factor: 4.415
2015 SCImago Journal Rankings: 2.322
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, RHSen_US
dc.contributor.authorYung, RWHen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorChau, PYen_US
dc.contributor.authorLam, WKen_US
dc.contributor.authorSo, SYen_US
dc.contributor.authorTodd, Den_US
dc.date.accessioned2012-09-05T05:15:20Z-
dc.date.available2012-09-05T05:15:20Z-
dc.date.issued1990en_US
dc.identifier.citationAntimicrobial Agents And Chemotherapy, 1990, v. 34 n. 2, p. 215-218en_US
dc.identifier.issn0066-4804en_US
dc.identifier.urihttp://hdl.handle.net/10722/161826-
dc.description.abstractThe efficacy of ofloxacin in preventing infection in neutropenic patients following cytotoxic chemotherapy was evaluated and was compared with that of co-trimoxazole. A total of 102 patients with hematological malignancies were randomly selected to receive either co-trimoxazole or ofloxacin. All patients were monitored for compliance, occurrence of infection, and drug-related side effects. A surveillance culture of a rectal swab was performed regularly. A total of 25 of the 52 patients (48%) who received co-trimoxazole and 11 of the 50 patients (22%) who received ofloxacin developed fever during the study period (P < 0.025). Gram-negative bacteremia occurred in nine patients in the co-trimoxazole group (17%) but in only one patient (2%) in the ofloxacin group (P < 0.05). No patient in either group had documented gram-positive bacterial or Pneumocystis carinii infection. Poor performance status was the only identifiable factor associated with an increased incidence of bacteremia. The surveillance study showed that significantly fewer bacterial strains were resistant to ofloxacin than to co-trimoxazole and that acquisition of resistance to co-trimoxazole was more commonly observed than was acquisition of resistance to ofloxacin. Significantly more patients had skin rashes following co-trimoxazole than ofloxacin treatment (P < 0.05). Ofloxacin was superior to co-trimoxazole in preventing infection in this population of neutropenic patients.en_US
dc.languageengen_US
dc.relation.ispartofAntimicrobial Agents and Chemotherapyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAgranulocytosis - Complicationsen_US
dc.subject.meshAntineoplastic Agents - Adverse Effectsen_US
dc.subject.meshBacterial Infections - Complications - Drug Therapy - Microbiologyen_US
dc.subject.meshChilden_US
dc.subject.meshFemaleen_US
dc.subject.meshGram-Negative Bacteria - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeutropenia - Chemically Induced - Complicationsen_US
dc.subject.meshOfloxacin - Therapeutic Useen_US
dc.subject.meshTrimethoprim-Sulfamethoxazole Combination - Therapeutic Useen_US
dc.titleOfloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapyen_US
dc.typeArticleen_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1128/AAC.34.2.215-
dc.identifier.pmid2327768-
dc.identifier.scopuseid_2-s2.0-0025098262en_US
dc.identifier.volume34en_US
dc.identifier.issue2en_US
dc.identifier.spage215en_US
dc.identifier.epage218en_US
dc.identifier.isiWOS:A1990CL83900007-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US
dc.identifier.scopusauthoridYung, RWH=7005594277en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChau, PY=36509704300en_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridSo, SY=7102397816en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats